Resverlogix Corp. (TSE:RVX – Get Free Report) shares hit a new 52-week high on Friday . The stock traded as high as C$0.09 and last traded at C$0.09, with a volume of 305200 shares. The stock had previously closed at C$0.09.
Resverlogix Stock Performance
The firm has a market capitalization of C$24.93 million, a PE ratio of -1.80 and a beta of 0.71. The firm has a 50-day moving average of C$0.06 and a two-hundred day moving average of C$0.06.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- Investing In Automotive Stocks
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- How to Calculate Stock Profit
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
